1. Introduction
As a leading cause of impaired limb viability, peripheral arterial disease (PAD)
is a progressive atherosclerotic process by which blood vessel narrowing or
occlusion occurs in the extremities [1]. Owing to poor blood perfusion, local
ischemia can induce serial pathophysiological responses in skeletal muscle tissue
[2], including tissue necrosis, inflammation, angiogenesis, and tissue
regeneration [3, 4].
Angiogenesis, defined as new capillaries formation from preexisting vasculature,
is mainly triggered by tissue ischemia or hypoxia [5]. Generation of new
microvasculature is critical in the condition of PAD, as angiogenesis can promote
the restoration of post-ischemic blood perfusion to skeletal muscle [6].
Therapeutic angiogenesis with the goal of stimulating new blood vessel formation
within ischemic tissues, has received extensive attention for PAD treatment [7].
Therefore, the development of molecular imaging approaches to noninvasively
monitor the recovery process of peripheral ischemic lesions would have
significant clinical benefits.
Numerous factors have been involved in the angiogenic process in the setting of
PAD [8]. Vascular endothelial growth factor (VEGF) has been recognized as one of
the most effective stimuli to the development of vascular network [9]. Apart from
VEGF, integrins also play a crucial role in the regulation of angiogenesis [10].
These transmembrane receptors are able to modulate cell adhesion, migration, and
proliferation. Particularly integrin has aroused
great interest among researchers owing to its significant role in the regulation
of endothelial cell migration and interplay with the extracellular matrix (ECM)
during angiogenesis [11]. The integrin has great
abundance on the surface of the endothelium with high angiogenic activity. Thus,
integrin has become the primary target of many
specific probes for noninvasive evaluation of angiogenesis, including
arginine-glycine-aspartic acid (RGD)-containing peptides.
Radiolabeled RGD peptides, targeted at integrin,
have been widely utilized for angiogenesis imaging in tumor. However,
angiogenesis not only occurs in cancer development but also is a critical
contributor to the improvement and recovery of ischemic lesions. After myocardial
ischemia/reperfusion (MI/R) injury, integrin
expression in cardiac tissue has been noninvasively monitored by numerous
isotopes including mTc [12], In [13], I [14, 15] by single
photon emission computed tomography (SPECT), and F [16] and Ga [17]
by positron emission tomography (PET). In addition, previous studies also have
used iodine-125 (I)- and mTc-labeled [16] RGD peptides to
visualize and quantify the activated angiogenesis post limb ischemia by targeting
integrin. Due to better imaging quality, higher
diagnostic accuracy and lower injection doses, PET imaging has been more widely
used for clinical imaging than SPECT imaging. Among multiple positron-emitting
radioisotopes for PET imaging, F is ideal for the development of RGD
peptide-based angiogenesis-targeted PET radiotracers as a result of its favorable
physical properties [18].
Most approaches labeling RGD peptides with F involve multiple-step
synthetic procedure [19], which is time-consuming and may hamper the widespread
use of these F-labeled RGD tracers. With the development of molecular
imaging, the labeling procedure can be simplified by linking RGD peptides with a
pre-attached functional group, which contains an active component available for
fluoride displacement [18, 20]. In our previous studies [21], we have applied a
one-step labeled tracer F-AlF-NOTA-PRGD2 (F-PRGD2) of
integrin-targeted in a rat model of experimental MI/R. Owing to easy synthesis
and high imaging quality, PET imaging using F-PRGD2 tracer achieved
successful evaluation of angiogenesis in infarcted cardiac tissue after MI/R
[21].
In this study, we established a mouse hindlimb ischemia (HI) model and microPET
was performed with the F-PRGD2 tracer to assess
integrin expression level during angiogenesis
progression in ischemic hindlimb. In addition, the angiogenic response to VEGF
treatment was also monitored with this F-PRGD2 tracer.
2. Materials and Methods
2.1 Animals
To eliminate the potential impact of gender bias, exclusively male mice were
used in the present study. FVB male mice were acquired from the Experimental
Animal Center of Zhongshan Medical University, weighing 25–30 g and aged 8–9
weeks. All processes involving surgical operation and imaging scans were
performed under anesthesia with isoflurane in oxygen (1.0–2.0%) with a delivery
flow rate of 1.0 L/min. After surgery, meloxicam (10 mg/kg SC) was injected near
the wound before mice completely awoke from anesthesia. Mice were sacrificed by
cervical dislocation. All animal procedures were performed in accordance with the
Guidelines for the Care and Use of Laboratory Animals and were approved by the
Animal Ethics Committee of Guangdong Academy of Medical Sciences [22].
2.2 Hindlimb Ischemic Murine Model
After hair removal on both hindlimbs by depilatory cream, an incision was made
through the skin of the thigh to expose the superficial arteries, veins, and
nerves. After careful separation of the arteries, veins, and nerves, the main
femoral artery and all branches in the right hindlimb were ligated and excised
with femoral nerves carefully preserved. The similar procedure was performed in
the left hindlimb except for the ligation and excision of the femoral artery,
which was a sham operation and served as a control.
2.3 Laser Doppler Perfusion Imaging (LDPI) of Hindlimbs
Laser Doppler perfusion imaging (LDPI) was used to evaluate blood perfusion in
preoperative and postoperative hindlimbs, respectively. After being anesthetized,
mice were placed on a heating pad to maintain a stable body temperature, and were
imaged using an analyzer (PeriScanPIM3 Perimed AB, Jakobsberg, Sweden).
2.4 Power Doppler Imaging (PDI) and Color Doppler Imaging (CDI) of
Hindlimbs
To detect the blood flow in hindlimbs, power Doppler and color Doppler scans
were performed with a Vevo 2100 imaging system (VisualSonics, Inc., Toronto, ON,
Canada) before surgery and one day after surgery. After the induction of
anesthesia, the vessel velocity and spatial distribution within the right
hindlimb were monitored using a linear transducer in three-dimensional mode in
power Doppler scans. Color Doppler mode in three-dimension was also applied to
achieve an overview of blood flow as well as the flow direction by red and blue
color spectrums in the right hindlimbs of pre-surgery and post-surgery,
respectively.
2.5 Small Animal PET Imaging
As previously described [23], an Inveon small-animal microPET scanner (Siemens
Preclinical Solutions) was used to perform PET imaging. After the induction of
anesthesia, a single dose of 100 L phosphate buffered saline (PBS) containing approximately 3.75 MBq
(100 Ci) of F-AlF-NOTA-PRGD2 (F-PRGD2) was
injected via the tail vein. One hour after the tracer injection, static PET
imaging scans were performed for 10 minutes. The acquired images were
reconstructed with an algorithm, known as three-dimensional ordered subsets
expectation maximization (3D-OSEM). ASI Pro VMTM software (Siemens Medical
Solutions, Germany) was also used for image analysis. The F-PRGD2
accumulation within the ischemic hindlimb tissue was quantified by drawing
regions of interest (ROIs) surrounding an entire limb on the coronal images in a
three-dimensional manner. The mean radioactivity contained in the ROI divided by
the dose administered to the animal gave the %ID per g (%ID/g). Then the tracer
uptake of the ischemic right hindlimb divided by the tracer uptake of the
contralateral left hindlimb gave the F-PRGD2 uptake ratio
(ischemic/control).
2.6 Immunohistochemistry (IHC) Assay
Mice from various groups or at different time points after surgery were
sacrificed and the skeletomuscular tissues of right hindlimbs were collected,
underwent fixation in 4% paraformaldehyde solution, dehydration through graded
solutions of ethanol, and paraffin embedding. Serial sections (5 m thick)
were cut and mounted on glass slides (p-45118, Fisher, Pittsburgh, PA, USA). The slides were
then dewaxed, processed by microwave antigen retrieval, and subsequently
incubated with 10% normal goat serum for 1 h and then overnight at 4 C
with CD31 antibody (mouse monoclonal, 1:100; #131M-9, Sigma, Burlington, MA, USA). The secondary
antibody was anti-mouse IgG (#21538-M, Sigma, Burlington, MA, USA), which was detected with
streptavidin–peroxidase complex and 0.1% of 3,3-diaminobenzidine (#D8001, Sigma, Burlington, MA, USA) in PBS with 0.05% HO for 5 min at room temperature. In
addition, hematoxylin and eosin (H&E) staining was also performed for tissue
morphology analysis.
For quantification, skeletal muscle tissue of each mouse was divided into
several parts, and about 10–20 slides were made from each sample. These slides
were divided into two parts, one part for CD31 staining and the other part for
integrin 3 staining. Capillaries (CD31 positive) density was determined
by the average counts of 10 random microscopic fields, which was expressed as the
number of capillaries per mm.
2.7 Immunofluorescence Assay
To achieve double antibody staining, slides were concurrently incubated with
both rabbit anti-integrin 3 (diluted 1:200; #ab179473, Abcam,
Cambridge, MA, USA) and mouse anti--actin (skeletal) primary antibodies
solution (diluted 1:250; #ab28052, Abcam, Cambridge, MA, USA). The combinations
were visualized using a mixture of Cy3-conjugated anti-rabbit (#AP182C, Sigma, Burlington, MA, USA) and fluorescein isothiocyanate (FITC)-conjugated anti-mouse (#AP124F,
Sigma, Burlington, MA, USA) secondary antibodies.
2.8 Experimental Protocols
In order to validate the success of HI model, PDI and CDI of the right hindlimb
were performed before surgery and after surgery (n = 3), respectively.
To assess the binding specificity of F-PRGD2 to integrin receptor in
ischemic tissue, twenty mice were randomly divided into four groups, including
sham, HI, block and RAD. Each group contained 5 mice. In the sham group, both
hindlimbs of mice were subjected to sham operation. Apart from the sham group,
mice underwent HI surgery in the right hindlimb as well as sham operation in the
left hindlimb in the other three groups. In both sham (sham, n = 5) and HI group
(HI, n = 5), approximately 100 Ci F-PRGD2 was injected one hour
before PET imaging scans on day 7 after surgery. Cyclic RGD peptide dimer
E[c(RGDyK)] served as a blocking agent (18 mg/kg) and was injected 10 min
before F-PRGD2 administration on day 7 after HI (block, n = 5). The
control peptide RAD was synthesized by a similar procedure as RGD producing
F-AlF-NOTA-RAD, which was injected via tail vein one hour before the PET
scan on day 7 after HI (RAD, n = 5).
For in vivo imaging of angiogenesis induced by HI, PET scan was
performed in a range of time points including day 0 (pre-surgery) and days 3, 7,
14, and 21 post surgery (n = 6).
For the treatment study, after the surgery of HI, a single dose of 100 L
PBS containing 0.5 g VEGF was injected into ischemic gastrocnemius muscles
below the site of occlusion at three different sites at 3 days and daily
thereafter for three consecutive days (HI + VEGF, n = 5). The same amount of PBS
without VEGF was administered in the same way at the same time points post
ischemia (HI, n = 5). In addition, a sham group was also included on day 7 after
sham operation (sham, n = 5).
Eight mice were sacrificed for histological staining. Thus, a total of 52 mice
were used in the present study.
2.9 Statistical Analysis
Results are presented as the mean standard deviation (SD). Statistical analysis was performed
using one-way analysis of variance (ANOVA) followed by the Bonferroni multiple comparison test. The
correlation of tracer uptake ratio and angiogenic activity was examined by the
Pearson correlation test. p 0.05 was considered as statistically
significant.
3. Results
3.1 Establishment of the Murine Model of Hindlimb Ischemia (HI)
Firstly, we established a murine HI model to mimic PAD. Unilateral HI was
induced by ligation and excision of the right femoral artery as well as excision
of its side branches. Subsequently, blood perfusion in the hindlimb was detected
by multiple imaging modalities, including Laser Doppler perfusion imaging (LDPI),
Power Doppler imaging (PDI), and Color Doppler imaging (CDI), all of which showed
the blood flow within the right hindlimb was precipitously reduced post surgery,
as compared to blood flow before surgery (Fig. 1). Additionally, both PDI and CDI
revealed the lack of side branches originating from the stem femoral artery after
surgery which were intact before surgery (Fig. 1). These results confirmed the
successful establishment of the murine HI model.
Fig. 1.
Characterization of a murine hindlimb ischemia (HI) model.
Before surgery and one day post-surgery, blood flow in right hindlimb
was detected by Power Doppler (PDI), Color Doppler (CDI) and Laser Doppler
imaging (LDI), respectively. Red and blue colors acquired by CDI represents blood
flow with different directions, which flows toward and away from the transducer.
3.2 Binding Specificity of F-PRGD2 to Integrin Receptor
The chemical structure of F-AlF-NOTA-PRGD2 (F-PRGD2) is shown in
Supplementary Fig. 1. When the reaction volume was maintained between 50
and 100 L, the labeling yield was about 20–25%. Without HPLC
purification, the total synthesis time was reduced to 25 minutes. The
radiochemical purity was over 97%. Fig. 2 showed significant increase of focal
tracer retention at 7 days after onset of ischemia (10.33 3.567) compared
to sham (1.227 0.368). In order to further confirm the binding
specificity of F-PRGD2 to integrin receptor, we utilized non-radiolabeled
integrin-specific ligand, E[c(RGDyK)], as a blocking agent. In vivo PET
imaging demonstrated that the F-PRGD2 uptake ratio in the blocked group
(3.45 2.186) was markedly lower than that in the unblocked group one week
post HI, indicating the tracer accumulation in the ischemic skeletal muscle could
be prevented by excess amount of unlabeled RGD peptide. A similar procedure was
also performed to label a RAD peptide. After using this labeled RAD peptide, we
found that the tracer uptake (3.308 1.431) was significantly lower than
that of F-PRGD2 at 7 days after HI (Fig. 2B). The low uptake of the
control peptide supports specific binding of F-PRGD2 to the ischemic area
rather than nonspecific leakage through injured vasculature. These results prove
the specificity of integrin-targeted imaging.
Fig. 2.
Specificity of integrin-targeted PET imaging. (A)
Representative transaxial PET images using F-AlF-NOTA-PRGD2
(F-PRGD2) (HI: 10.33 3.707, n = 5), or with a block reagent
(block: 3.45 2.168, n = 5), or F-AlF-NOTA-RAD (RAD: 3.308
1.431, n = 5) at 7 days after HI surgery. F-PRGD2 was also used in mice
which underwent a sham operation (sham: 1.227 0.368, n = 5). (B)
Quantification of F-PRGD2 uptake ratio (ischemic/control hindlimb) by PET
at different groups. **p 0.01; ***p
0.001.
3.3 In Vivo PET Imaging of Angiogenesis Induced by HI
To monitor angiogenesis after HI, longitudinal PET imaging using F-PRGD2
probe was performed at serial time points including day 0 (pre-surgery) and at
days 3, 7, 14, and 21 post surgery. Fig. 3A shows representative transaxial PET
images with F-PRGD2. Compared with day 0, an increase of F-PRGD2
tracer uptake could be quickly detected as early as day 3 after HI and reached a
maximum at day 7, which was consistent with most previous studies [17, 24]. The
signal then gradually reduced in the following days. The quantitative results
based on PET imaging are presented in Fig. 3C. The hindlimb uptake ratio of
F-PRGD2 in the pre-surgery group was minimal (1.249 0.296). HI
injury led to a significant increase in uptake ratio of F-PRGD2 in the
ischemic hindlimb at 3 days (5.483 1.354) post surgery. Radiotracer
localization after onset of ischemia was maximal at 7 days (13.34 5.169).
Although decreased by 3 weeks, the uptake of the radiotracer was still greater
than that in the pre-surgery group.
Fig. 3.
Close correlation between angiogenesis and F-PRGD2
uptake. (A) Representative transaxial PET images using (F-PRGD2) at day 0
(pre-surgery) and days 3, 7, 14, and 21 post surgery, respectively. (B) CD31
positive vessels were immunohistochemically detected on day 0 and days 3, 7, 14
and 21 post-surgery, respectively. (C) Analysis of F-PRGD2 uptake ratio
(ischemic/control hindlimb) by PET at a serial of time points (day 0: 1.249
0.296, n = 6; day 3: 5.483 1.354, n = 6; day 7: 13.34
5.169, n = 6; day 14: 7.397 3.434, n = 6; day 21: 3.2 0.804, n =
6). (D) Quantitative analysis of CD31 capillary density at a series of time
points post-surgery (day 0: 30.83 8.159, n = 6; day 3: 71.33
12.01, n = 6; day 7: 184.5 20.21, n = 6; day 14: 143.2 20.11, n =
6; day 21: 90.5 15.1, n = 6). (E) Correlation analysis between
F-PRGD2 uptake ratio (ischemic/control) and angiogenic activity, which is
represented by capillary numbers (R = 0.8691, p =
0.0209). *p 0.05; **p 0.01; ***p 0.001.
Scale bar: 100 m.
Skeletal muscle tissues were also harvested at various time points before and
after surgery for histological analysis. IHC staining was performed using CD31, a
maker for endothelial cells. As shown in Fig. 3B, numerous neutrophils (nuclei in
blue or purple) were infiltrated from the damaged lumen, evidenced by
discontinuous endothelial layer (highlighted by brown color). These signs
indicated intense inflammation in this period. Thereafter, angiogenesis was
robustly activated and reached a peak at day 7 (184.5 20.21), as
quantified by CD31 staining (Fig. 3D). In the following two weeks, angiogenesis
continued within ischemic muscle, yet with gradually reduced activity.
Additionally, correlation analysis was also performed between F-PRGD2
uptake ratio (ischemic/control) and angiogenesis, which is indicated by capillary
numbers. As demonstrated in Fig. 3E, there was a strong correlation between these
two variables (p = 0.0209). On the basis of the similar temporal changes
and positive correlation between angiogenic activity and F-PRGD2 uptake
ratio, we believe that the fluctuation of F-PRGD2 uptake was able to
reflect the variation of angiogenesis in ischemic tissue.
3.4 In Vivo Assessment of Angiogenic Response to Therapy
As one of the most established angiogenesis stimuli, VEGF was chosen in the
present study for HI treatment. Compared with the non-treated HI group at 7 days
post-surgery (167 19.24), newly formed capillaries stained with CD31 were
found to be elevated after treated with VEGF (208.7 26.28) (Fig. 4A,C).
Given the fact that the alteration of F-PRGD2 uptake ratio is positively
correlated with angiogenic activity during HI, we then determined whether PET
imaging with F-PRGD2 probe could be applied to evaluate the angiogenic
response to therapy. As Fig. 4B showed, the signal intensity in the region of
ischemic hindlimbs in the VEGF-treated group was significantly stronger than in
the non-treated group. Based on the quantification of PET imaging, the
F-PRGD2 uptake ratio of ischemic region in the VEGF-treated group (17.25
2.441) was nearly fifteen times higher than that in the sham group (1.269
0.325), while the uptake ratio of ischemic region in the non-treated
group (12.67 3.438) was only about ten times higher than that in the sham
group (Fig. 4D).
Fig. 4.
Evaluation of VEGF treatment on angiogenic activity. (A)
Ex vivo immunohistochemical (IHC) staining of CD31 to examine
angiogenesis in the ischemic hindlimb tissue sections 7 days post surgery in the
sham-operated groups (sham), no-treatment (HI) and VEGF-treated group (HI +
VEGF), respectively. (B) In vivo noninvasive PET imaging of angiogenesis
at 7 days after surgery in different groups. (C) Quantitative analysis of CD31
capillary density (sham: 44.33 13.29, n = 6; HI: 167 19.24, n = 6;
HI + VEGF: 208.7 26.28, n = 6). (D) Quantification of F-PRGD2 uptake
ratio (ischemic/control hindlimb) from in vivo PET imaging (sham: 1.269
0.325, n = 5; HI: 12.67 3.438, n = 5; HI + VEGF: 17.25
2.441, n = 5). *p 0.05; **p 0.01; ***p
0.001. Scale bar: 100 m.
According to the immunofluorescence staining, the integrin 3 level in
the VEGF-treated group (HI + VEGF) was higher than in both saline-treated group
(HI) and sham group (sham) (Fig. 5), which was consistent with the pattern of
radioactive signal as demonstrated by in vivo PET imaging. These results
suggested that the F-PRGD2 uptake ratio was positively correlated with
integrin 3 level within ischemic area and it could serve as a tool for
noninvasive evaluation of the HI treatment response.
Fig. 5.
Immunofluorescence staining of integrin 3 in the
VEGF-treated (HI + VEGF), no-treatment (HI) and sham-operated groups (sham). Scale
bar: 200 m.
4. Discussion
In the present study, we reported for first time the application of a one-step
labeled PET tracer F-AlF-NOTA-PRGD2 (F-PRGD2), for the noninvasive
monitoring of temporal changes of integrin level
during ischemia-induced angiogenesis in a mouse HI model. In addition, we used
this tracer to evaluate the angiogenic response to VEGF treatment.
Although molecular imaging techniques have not yet reached the standard for
clinical application for imaging peripheral angiogenesis, extensive preclinical
work has demonstrated that noninvasive serial analysis of angiogenesis is
achievable and holds great promise for clinical translation with primary targets
including integrin [25]. Lee et al. [26]
used iodine-125 (I)-labeled RGD peptides for
integrin targeting in mouse HI model with SPECT
imaging and observed that radiotracer uptake reached a peak on day 3 and was
maintained at a relatively lower level at 8 and 14 days of ischemia, but still
higher than at the onset of ischemia. Furthermore, serial changes of
integrin expression were also noninvasively
assessed with mTc-NC100692 probe during the angiogenic process in the
ischemic hindlimb. Imaging results demonstrated a significantly enhanced
radiotracer uptake at 3 days and a peak at 7 days [24]. In addition, Jeong
et al. [17] used Ga-NOTA-RGD as the PET imaging tracer and
investigated its biodistribution at 7 days after femoral artery ablation in mice
and demonstrated its high affinity for the
integrin and specific uptake by angiogenic hindlimb tissue. In the current study,
for the first time, we applied a one-step labeled PET tracer F-PRGD2 to
evaluate the temporal changes of integrin
expression in mouse hindlimb tissue exposed to ischemia. Our imaging results with
F-PRGD2 displayed a similar pattern of tracer uptake in the ischemic
region as in earlier work. The significant increase of focal tracer retention
could be quickly observed at 3 days post ischemia. Apart from the formation of
newly regenerated capillaries at this time, shown by CD31 staining, intensive
inflammation occurred after HI which also accounted for the high uptake of
F-PRGD2 since integrin is highly expressed
on infiltrating macrophages [27]. Indeed, IHC staining (Fig. 3B) revealed that a
large number of inflammatory cells had infiltrated among affected skeletal muscle
on day 3 after surgery. The tracer accumulation reached a maximum on day 7.
Thereafter, F-PRGD2 uptake within the ischemic hindlimb decreased from the
peak level but was still higher than that in the sham-operated hindlimb,
suggesting local continuous angiogenesis.
When VEGF treatment was applied, the F-PRGD2 uptake in the ischemic area
was elevated and associated with increase of
integrin expression, which showed a similar tendency with angiogenesis
development after HI. Our data indicated that F-PRGD2 uptake is positively
correlated with angiogenic activity during HI and is able to increase in response
to VEGF treatment. It could serve as a prospective probe used to monitor the
angiogenic response post HI, which might help evaluate therapeutic effect of
pro-angiogenesis medications treating ischemic diseases in clinical practice.
Compared to other radiolabeled tracers in previous studies, the PET tracer
F-PRGD2 used here has several noticeable advantages. Firstly, when
compared to traditional SPECT imaging, continued growth in the use of PET imaging
in both pre-clinical and clinical work can be ascribed to increased availability
of hybrid with computed tomography (CT) or magnetic resonance imaging (MRI), providing high sensitivity as well as good spatial
resolution. Thus, PET radiotracers targeting angiogenesis have been investigated
more extensively than SPECT radiotracers. In addition, F has been
considered as an ideal radioisotope for PET imaging due to its physical
properties, including short physical half-life, high positron efficiency and low
+ energy. Secondly, as a dimeric RGD peptide tracer, F-PRGD2 has
better binding affinity to integrin than RGD
monomers, such as Galacto-RGD, resulting in higher integrin targeted accumulation
and more favorable in vivo kinetics. Thirdly, compared with another
previously used dimeric RGD peptide tracer F-FPPRGD2 [19], synthesis of
F-PRGD2 is efficient and consequently results in relatively high labeling
yield. This convenient one step route for labeling can be achieved by the
displacement of the F with a leaving group in a pre-attached chelator on
RGD peptides without the need of HPLC purification [18, 20]. Hence, it is
reasonable to surmise that the ideal physical properties and good binding
affinity as well as the simple labeling procedure would make F-PRGD2 a
very promising radiotracer for clinical translation in cardiovascular diseases.
5. Conclusions
PET imaging of a one-step labeled integrin-targeted probe,
F-AlF-NOTA-PRGD2 (F-PRGD2), enables longitudinal monitoring of
angiogenesis development and noninvasive assessment of VEGF treatment response in
mouse model of hindlimb ischemia. The simple synthesis procedure, specific
binding affinity and favorable in vivo performance of this PET tracer
may assist in screening pro-angiogenic drugs in the preclinical setting and
future clinical evaluation of ischemic lesion and therapy responses in patients
with ischemic cardiovascular diseases, especially peripheral arterial disease.
Author Contributions
ZS, NT and PH conceived and designed the study; ZS, WH, SX, LX and JY performed
major experiments; GT, LZ and JY established the animal model; WH, SX and GT
collected and analyzed the data; ZS, WH and SX wrote the manuscript; NT and PH
reviewed the manuscript; NT and PH supervised the study. All authors contributed
to editorial changes in the manuscript. All authors read and approved the final
manuscript.
Ethics Approval and Consent to Participate
The animal study was reviewed and approved by the Animal Ethics Committee of
Guangdong Academy of Medical Sciences (KY-D-2021-425-01).
Acknowledgment
We would like to express our gratitude to all the peer reviewers for their
opinions and suggestions.
Funding
This research was funded by the Guangdong Provincial People’s Hospital
Cardiovascular Research Fund, grant number 2020XXG004; National Natural Science
Foundation of China, grant number 82170461; Natural Science Foundation of
Guangdong Province, grant number 2021A1515011121; Science and Technology Program
of Guangzhou 202102080033; and National Natural Science Foundation of Guangdong
Provincial People’s Hospital, grant number 8207020425, 8217020758. None of these
funding sources had any role in writing the manuscript or the decision to submit
for publication.
Conflict of Interest
The authors declare no conflict of interest.